Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section
Other Events. On November 8, 2025, new data from the Company’s ongoing Phase 2b REZOLVE-AD trial was presented in a late-breaking oral session at the American C
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled “New Data from REZOLVE-AD Study of Rezpegaldesleukin Presente